Clinical observation on various frequency of palonosetron for preventing gastrointestinal adverse reaction induced by high-dosage cisplatin chemotherapy

objective To observe the clinical effects on various frequency of palonosetron for preventing gastrointestinal adverse reaction induced by high-dosage cisplatin chemotherapy. Methods The patients(84 cases) diagnosed as malignant tumor who were accepted high-dosage cisplatin chemotherapy in Shanghai Fengxian District Central Hospital from April 2010 to January 2014 were randomly divided into treatment(42 cases) and control(42 cases) groups. Patients in the control group were iv administered with Palonosetron Injection 0.25 mg/time 30 min before the treatment on day 1 of chemotherapy. Patients in the treatment group were iv administered with Palonosetron Injection 0.25 mg/time 30 min before the treatment on days 1, 3, and 5 of chemotherapy. All the patients were observed for one cycle of chemotherapy. Occurrence situations of vomiting, nausea, and loss of appetite were compared. Results In the acute phase, vomiting control efficiency in the control group was 78.57% and 83.33% in the treatment group, while the difference was no statistically significant between the two groups. In the delay phase, vomiting control efficiency in the control group was 52.38% and 61.90% in the treatment group, with the significant difference between the two groups(P 0.01). After the treatment, in the acute phase, the nausea efficiency in the control group was 61.90% and 76.19% in the treatment group. In delay phase, the nausea efficiency in the control group was 52.38% and 66.67% in the treatment group, with the significant difference between the two groups(P 0.01). In the acute phase, the loss of appetite control efficiency in the control group was 88.10% and 92.86% in the treatment group. In the delay phase, the loss of appetite control efficiency in control group was 85.71% and 90.48% in the treatment group, while the difference was no statistically significant between the two groups. Conclusion The frequency of palonosetron could be appropriately increased for preventing gastrointestinal adverse reaction induced by high-dosage cisplatin chemotherapy, but the increased risk of adverse reactions should be alerted.